스마트 체외진단 시장 : 체외진단 시장의 인공지능 - 용도별, 기술별, 장소별, 제품별 - 경영진 및 컨설턴트 가이드 포함(2025-2029년)

Smart In Vitro Diagnostics. Artificial Intelligence for IVD Markets by Application, By Technology, By Product and By User. With Executive and Consultant Guides 2025-2029

US $ 6,995 ￦ 9,583,000

PDF (Single User License)

PDF 보고서를 1명(One device)만 이용할 수 있는 라이선스입니다. 인쇄 불가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.

US $ 10,495 ￦ 14,379,000

PDF (Five User License)

PDF 보고서를 동일 사업장의 5명(Five devices)까지 이용할 수 있는 라이선스입니다. 인쇄 불가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.

US $ 13,995 ￦ 19,174,000

PDF (Enterprise License)

PDF 보고서를 동일 기업의 모든 분이 이용할 수 있는 라이선스입니다. 인쇄는 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.

한글목차

인공지능이 향후 20년간 체외진단 시장 성장을 견인할 것입니다. 의사가 모든 정보를 활용하여 질병과 싸우기 위해 모든 정보를 활용하기 때문에 시장은 폭발적으로 확대되고 있습니다. 한편, 제약회사들은 거의 모든 치료법을 실현할 수 있는 가능성을 발견하고 있습니다. 진단에 대한 이 새로운 접근 방식이 어떻게 의료를 변화시킬 수 있는지 알아보세요.

처음부터 새로이 만들어지는 시장에서 진입기업들은 어떻게 포지션 경쟁을 벌이고 있을까요? 일부 진입 기업들은 크게 앞서 나가고 있으며, 전 세계로 진출하고 있습니다. 적절한 진단약과 적절한 지원이 있다면 프리미엄 가격으로 거래될 수 있는 엄청난 기회가 있는 역동적인 시장 상황입니다. 또한, 과학이 발전함에 따라 새로운 기회도 주기적으로 생겨나고 있습니다. 그리고 많은 범용 진단 약품의 비용은 계속 하락하고 있습니다.

본 보고서에는 18개 국가와 4개 지역별 상세 분석이 포함되어 있습니다. 본 보고서를 구매하신 분들은 전 세계 모든 국가별 상세 내역을 보실 수 있습니다.

세계의 스마트 체외진단 시장에 대해 조사했으며, 시장 개요와 함께 용도별, 기술별, 지역별, 제품별 동향, 시장 진입 기업 프로파일 등의 정보를 전해드립니다.

목차

제1장 시장 가이드

제2장 소개와 시장 정의

• 스마트 진단이란 무엇인가?
• 시장 정의
• 조사 방법
• 관점 : 헬스케어와 IVD 업계

제3장 시장 개요

• 시장 진입 조직
  • 학술연구기관
  • 진단 시험 개발자
  • 계측 기기 공급업체
  • 약품·시약 제조업체
  • 병리 공급업체
  • 독립계 임상 검사실
  • 공공 국립/지역 연구소
  • 병원 검사실
  • 임상 검사실
  • 감사 기관
  • 인증 기관
• 인공지능을 이해
• IVD의 AI 응용

제4장 시장 동향

• 성장 촉진요인
• 성장 억제요인
• 계측, 자동화, 진단 동향

제5장 최근 동향

제6장 주요 기업 개요

• Adaptive Biotechnologies
• Aidoc
• Anumana
• ARUP Laboratories
• Atomwise
• Bayesian Health
• Behold.ai
• BGI Genomics Co. Ltd
• bioMerieux Diagnostics
• Bio-Rad Laboratories, Inc
• Cambridge Cognition
• Cardiologs(Phillips)
• CareDx
• Caris Molecular Diagnostics
• Cleerly
• ClosedLoop AI
• CloudMedX Health
• Deepcell
• Digital Diagnostics
• EKF Diagnostics Holdings
• Freenome
• GE Healthcare
• Glooko
• Idoven
• Illumina
• Infohealth
• Jade
• K Health
• Lunit
• Luventix
• MaxCyte
• Mayo Clinic Laboratories
• Medtronic
• Merative
• Nanox
• NIOX Group
• Niramai Health Analytix
• NVIDIA
• Oncohost
• OraLiva
• Owkin
• Oxford Nanopore Technologies
• Pacific Biosciences
• Paige.AI
• PathAI
• Perthera
• Philips Healthcare
• Prognos
• Qiagen
• Qure.ai
• Renalytix
• Seegene
• Siemens Healthineers
• Sophia Genetics
• Sysmex
• Viz.ai

제7장 세계의 스마트 체외진단 시장

• 국가별 세계 시장 개요
• 용도별 세계 시장 - 개요
• 기술별 세계 시장 - 개요
• 장소별 세계 시장 - 개요
• 제품별 세계 시장 - 개요

제8장 세계 시장 - 용도별

• 암
• 감염증 검사
• 대사 검사
• 심장 검사
• 당뇨병 검사
• 기타

제9장 세계 시장 - 기술별

• NGS 기술
• PCR 기술
• 화학/IA기술
• 병리학 기술
• 기타 기술

제10장 세계의 시장 - 장소별

• 연구
• 의약품 연구
• 임상
• 기타

제11장 세계의 시장 - 제품별

• 기기
• 어세이
• 소프트웨어
• 서비스
• 기타

제12장 부록

ksm

영문 목차

영문목차

Artificial Intelligence will drive IVD market growth over the next 20 years. The market is exploding as physicians use all the information they can get to battle disease. While Pharmaceutical Companies see the potential to make nearly any therapy viable. Find out how this new approach to diagnostics will change medical care forever.

Learn all about how players are jockeying for position in a market that is being created from scratch. And some players are pulling way out in front and expanding globally. It is a dynamic market situation with enormous opportunity where the right diagnostic with the right support can command premium pricing. And the science is developing at the same time creating new opportunities with regularity. And the cost of many commodity diagnostics continues to fall.

The report includes detailed breakouts for 18 Countries and 4 Regions. A detailed breakout for any country in the world is available to purchasers of the report.

Table of Contents

1. Market Guides

• 1.1. Strategic Situation Analysis
• 1.2. Guide for Executives, Marketing, and Business Development Staff
• 1.3. Guide for Management Consultants and Investment Advisors

2. Introduction and Market Definition

• 2.1. What are Smart Diagnostics?
• 2.2. Market Definition
  • 2.2.1. Revenue Market Size
• 2.3. Methodology
  • 2.3.1. Methodology
  • 2.3.2. Sources
  • 2.3.3. Authors
• 2.4. Perspective: Healthcare and the IVD Industry
  • 2.4.1. Global Healthcare Spending
  • 2.4.2. Spending on Diagnostics
  • 2.4.3. Important Role of Insurance for Diagnostics

3. Market Overview

• 3.1. Players in a Dynamic Market
  • 3.1.1. Academic Research Lab
  • 3.1.2. Diagnostic Test Developer
  • 3.1.3. Instrumentation Supplier
  • 3.1.4. Chemical/Reagent Supplier
  • 3.1.5. Pathology Supplier
  • 3.1.6. Independent Clinical Laboratory
  • 3.1.7. Public National/regional Laboratory
  • 3.1.8. Hospital Laboratory
  • 3.1.9. Physicians Office Lab (POLS)
  • 3.1.10. Audit Body
  • 3.1.11. Certification Body
• 3.2. Understanding Artificial Intelligence
  • 3.2.1. Artificial intelligence
  • 3.2.2. Machine learning
  • 3.2.3. Deep learning
  • 3.2.4. Convolutional neural networks
  • 3.2.5. Generative adversarial networks
  • 3.2.6. Limitations
• 3.3. AI Applications in IVD
  • 3.3.1. Infectious Disease
    • 3.3.1.1. Known vs. Unknown
    • 3.3.1.2. TMI
    • 3.3.1.3. Disease surveillance
    • 3.3.1.4. Outbreak detection
    • 3.3.1.5. Contact tracing
    • 3.3.1.6. Forecasting
    • 3.3.1.7. Drug discovery
    • 3.3.1.8. Resource allocation
  • 3.3.2. Oncology
    • 3.3.2.1. Electronic health records
    • 3.3.2.2. Genomic analysis
    • 3.3.2.3. Treatment planning
    • 3.3.2.4. Clinical trial matching
  • 3.3.3. Anatomic Pathology
    • 3.3.3.1. Image analysis
    • 3.3.3.2. Tumor segmentation
    • 3.3.3.3. Disease classification
    • 3.3.3.4. Predictive modeling
    • 3.3.3.5. Quality control
    • 3.3.3.6. Digital pathology
  • 3.3.4. Cardiology
    • 3.3.4.1. Electrocardiogram analysis
    • 3.3.4.2. Electronic health records
    • 3.3.4.3. Genomic analysis
    • 3.3.4.4. Treatment planning
    • 3.3.4.5. Prediction of outcomes
  • 3.3.5. Diabetes
    • 3.3.5.1. Diagnosis
    • 3.3.5.2. Blood glucose monitoring
    • 3.3.5.3. Personalized treatment plans
    • 3.3.5.4. Medication management
    • 3.3.5.5. Diabetes education
    • 3.3.5.6. Predictive analytics
  • 3.3.6. General Medicine
    • 3.3.6.1. Diagnosis
    • 3.3.6.2. Predictive Analytics
    • 3.3.6.3. Personalized Treatment Plans
    • 3.3.6.4. Medication Management
    • 3.3.6.5. Disease Monitoring
    • 3.3.6.6. Telemedicine

4. Market Trends

• 4.1. Factors Driving Growth
  • 4.1.1. Outcome Improvement
  • 4.1.2. The Aging Effect
  • 4.1.3. Cost Containment
  • 4.1.4. Physician Impact
  • 4.1.5. Cost of Intelligence
• 4.2. Factors Limiting Growth
  • 4.2.1. State of knowledge
  • 4.2.2. Genetic Blizzard
  • 4.2.3. Protocol Resistance
  • 4.2.4. Regulation and coverage
• 4.3. Instrumentation, Automation and Diagnostic Trends
  • 4.3.1. Traditional Automation and Centralization
  • 4.3.2. The New Automation, Decentralization and Point Of Care
  • 4.3.3. Instruments Key to Market Share
  • 4.3.4. Bioinformatics Plays a Role
  • 4.3.5. PCR Takes Command
  • 4.3.6. Next Generation Sequencing Fuels a Revolution
  • 4.3.7. NGS Impact on Pricing
  • 4.3.8. Whole Genome Sequencing, A Brave New World
  • 4.3.9. Companion Diagnostics Blurs Diagnosis and Treatment
  • 4.3.10. Shifting Role of Diagnostics

5. Recent Developments

• 5.1. Recent Developments - Importance and How to Use This Section
  • 5.1.1. Importance of These Developments
  • 5.1.2. How to Use This Section
• 5.2. Ataraxis AI Nabs Financing
• 5.3. Myriad Genetics Licenses Image Analysis Technology
• 5.4. Danaher, AI Firm I Form Investment Partnership
• 5.5. Cardio Dx AI-Based Tests Receive Final CMS Pricing
• 5.6. Ataraxis AI Launches AI Cancer Dx
• 5.7. Tempus Immuno-Oncology Portfolio AI-enabled
• 5.8. AI enables precision diagnosis of cervical cancer
• 5.9. UK to Rollout Digital Pathology Across NHS
• 5.10. AI Based Next-Generation Colorectal Cancer Test
• 5.11. Evident, Corista, Sakura Finetek, Visiopharm Form Digital Pathology Alliance
• 5.12. Viome Life Sciences Raises $86.5M in Oversubscribed Series C Round
• 5.13. Becton Dickinson Gets Clearance for AI-Based Bacterial Imaging
• 5.14. Paige, Leica Biosystems Expand Digital Pathology Partnership
• 5.15. Clarapath Acquires Digital Pathology Company Crosscope
• 5.16. CanSense to Develop Colorectal Cancer Test
• 5.17. Owkin-led Machine Learning Study IDs Cancer Treatment Biomarkers
• 5.18. Guardant Health to Integrate Lunit's AI PD-L1 Algorithm
• 5.19. Vesale Bioscience to Develop AI Phage Therapy Diagnostic Platform
• 5.20. Caris Life Sciences To Use AI and Machine Learning
• 5.21. Numares Health To Develop AI for "Metabolite Constellations"
• 5.22. Sepsis Testing Startup DeepUll to Use AI for Medical Decisions
• 5.23. Viome Life Sciences Raises $67M in Series C Financing For AI Cancer Dx
• 5.24. ADM Diagnostics Wins Grant for Brain Injury Test Development
• 5.25. Paige to Develop New AI-based Pathology Test
• 5.26. Aiforia Gains CE-IVD Mark for AI-Powered Histopathology
• 5.27. Genetic Profiling May Identify Patients Who Do Not Need Radiation Therapy
• 5.28. Thermo Fisher Introduces Homologous Score for Cancer Profiling
• 5.29. Genomic Test IDs Cancer Cells Early

6. Profiles of Key Players

• 6.1. Adaptive Biotechnologies
• 6.2. Aidoc
• 6.3. Anumana
• 6.4. ARUP Laboratories
• 6.5. Atomwise
• 6.6. Bayesian Health
• 6.7. Behold.ai
• 6.8. BGI Genomics Co. Ltd
• 6.9. bioMerieux Diagnostics
• 6.10. Bio-Rad Laboratories, Inc
• 6.11. Cambridge Cognition
• 6.12. Cardiologs (Phillips)
• 6.13. CareDx
• 6.14. Caris Molecular Diagnostics
• 6.15. Cleerly
• 6.16. ClosedLoop AI
• 6.17. CloudMedX Health
• 6.18. Deepcell
• 6.19. Digital Diagnostics
• 6.20. EKF Diagnostics Holdings
• 6.21. Freenome
• 6.22. GE Healthcare
• 6.23. Glooko
• 6.24. Idoven
• 6.25. Illumina
• 6.26. Infohealth
• 6.27. Jade
• 6.28. K Health
• 6.29. Lunit
• 6.30. Luventix
• 6.31. MaxCyte
• 6.32. Mayo Clinic Laboratories
• 6.33. Medtronic
• 6.34. Merative
• 6.35. Nanox
• 6.36. NIOX Group
• 6.37. Niramai Health Analytix
• 6.38. NVIDIA
• 6.39. Oncohost
• 6.40. OraLiva
• 6.41. Owkin
• 6.42. Oxford Nanopore Technologies
• 6.43. Pacific Biosciences
• 6.44. Paige.AI
• 6.45. PathAI
• 6.46. Perthera
• 6.47. Philips Healthcare
• 6.48. Prognos
• 6.49. Qiagen
• 6.50. Qure.ai
• 6.51. Renalytix
• 6.52. Seegene
• 6.53. Siemens Healthineers
• 6.54. Sophia Genetics
• 6.55. Sysmex
• 6.56. Viz.ai

7. The Global Market for Smart Diagnostics

• 7.1. Global Market Overview by Country
  • 7.1.1. Table - Global Market by Country
  • 7.1.2. Chart - Global Market by Country
• 7.2. Global Market by Application - Overview
  • 7.2.1. Table - Global Market by Application
  • 7.2.2. Chart - Global Market by Application - Base/Final Year Comparison
  • 7.2.3. Chart - Global Market by Application - Base Year
  • 7.2.4. Chart - Global Market by Application - Final Year
  • 7.2.5. Chart - Global Market by Application - Share by Year
  • 7.2.6. Chart - Global Market by Application - Segment Growth
• 7.3. Global Market by Technology - Overview
  • 7.3.1. Table - Global Market by Technology
  • 7.3.2. Chart - Global Market by Technology - Base/Final Year Comparison
  • 7.3.3. Chart - Global Market by Technology - Base Year
  • 7.3.4. Chart - Global Market by Technology - Final Year
  • 7.3.5. Chart - Global Market by Technology - Share by Year
  • 7.3.6. Chart - Global Market by Technology - Segment Growth
• 7.4. Global Market by Place - Overview
  • 7.4.1. Table - Global Market by Place
  • 7.4.2. Chart - Global Market by Place - Base/Final Year Comparison
  • 7.4.3. Chart - Global Market by Place - Base Year
  • 7.4.4. Chart - Global Market by Place - Final Year
  • 7.4.5. Chart - Global Market by Place - Share by Year
  • 7.4.6. Chart - Global Market by Place - Segment Growth
• 7.5. Global Market by Product - Overview
  • 7.5.1. Table - Global Market by Product
  • 7.5.2. Chart - Global Market by Product - Base/Final Year Comparison
  • 7.5.3. Chart - Global Market by Product - Base Year
  • 7.5.4. Chart - Global Market by Product - Final Year
  • 7.5.5. Chart - Global Market by Product - Share by Year
  • 7.5.6. Chart - Global Market by Product - Segment Growth

8. Global Markets - By Application

• 8.1. Cancer
  • 8.1.1. Table Cancer Testing - by Country
  • 8.1.2. Chart - Cancer Testing Growth
• 8.2. Infectious Disease Testing
  • 8.2.1. Table Infectious Disease Testing - by Country
  • 8.2.2. Chart - Infectious Disease Testing Growth
• 8.3. Metabolic Testing
  • 8.3.1. Table Metabolic Testing - by Country
  • 8.3.2. Chart - Metabolic Testing Growth
• 8.4. Cardiac Testing
  • 8.4.1. Table Cardiac Testing - by Country
  • 8.4.2. Chart - Cardiac Testing Growth
• 8.5. Diabetes Testing
  • 8.5.1. Table Diabetes Testing - by Country
  • 8.5.2. Chart - Diabetes Testing Growth
• 8.6. Other Disease Testing
  • 8.6.1. Table Other Disease Testing - by Country
  • 8.6.2. Chart - Other Disease Testing Growth

9. Global Markets - By Technology

• 9.1. NGS Technology
  • 9.1.1. Table NGS Technology - by Country
  • 9.1.2. Chart - NGS Technology Growth
• 9.2. PCR Technology
  • 9.2.1. Table PCR Technology - by Country
  • 9.2.2. Chart - PCR Technology Growth
• 9.3. Chemistry/IA Technology
  • 9.3.1. Table Chemistry/IA Technology - by Country
  • 9.3.2. Chart - Chemistry/IA Technology Growth
• 9.4. Pathology Technology
  • 9.4.1. Table Pathology Technology - by Country
  • 9.4.2. Chart - Pathology Technology Growth
• 9.5. Other Technology
  • 9.5.1. Table Other Technology - by Country
  • 9.5.2. Chart - Other Technology Growth

10. Global Markets - By Place

• 10.1. Research
  • 10.1.1. Table Research - by Country
  • 10.1.2. Chart - Research Growth
• 10.2. Pharmaceutical Research
  • 10.2.1. Table Pharmaceutical Research - by Country
  • 10.2.2. Chart - Pharmaceutical Research Growth
• 10.3. Clinical
  • 10.3.1. Table Clinical - by Country
  • 10.3.2. Chart - Clinical Growth
• 10.4. Other Place
  • 10.4.1. Table Other Place - by Country
  • 10.4.2. Chart - Other Place Growth

11. Global Markets - By Product

• 11.1. Instruments
  • 11.1.1. Table Instruments - by Country
  • 11.1.2. Chart - Instruments Growth
• 11.2. Assay
  • 11.2.1. Table Assay - by Country
  • 11.2.2. Chart - Assay Growth
• 11.3. Software
  • 11.3.1. Table Software - by Country
  • 11.3.2. Chart - Software Growth
• 11.4. Services
  • 11.4.1. Table Services - by Country
  • 11.4.2. Chart - Services Growth
• 11.5. Other Product
  • 11.5.1. Table Other Product - by Country
  • 11.5.2. Chart - Other Product Growth

12. Appendices

• 12.1. United States Clinical Laboratory Fees Schedule
  • 12.1.1. Laboratory Fees Schedule
  • 12.1.2. The Most Used IVD Assays
  • 12.1.3. The Highest Grossing Assays

관련자료